Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer.

Wildiers, H; Fontaine, C; Vuylsteke, P; Martens, M; Canon, J L; Wynendaele, W; Focan, C; De Greve, J; Squifflet, P; Paridaens, R

Wildiers, H; Fontaine, C; Vuylsteke, P; Martens, M; Canon, J L; Wynendaele, W; Focan, C; De Greve, J; Squifflet, P; Paridaens, R.

Affiliation

Wildiers H; Department of General Medical Oncology/Multidisciplinary Breast Centre, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. hans.wildiers@uzleuven.be

Breast Cancer Res Treat ; 123(2): 463-9, 2010 Sep.

Article in En | MEDLINE | ID: mdl-20652398

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/drug therapy; Receptor, ErbB-2/analysis; Adult; Aged; Angiogenesis Inhibitors/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Belgium; Breast Neoplasms/chemistry; Breast Neoplasms/mortality; Breast Neoplasms/pathology; Disease-Free Survival; Female; Humans; Indoles/administration & dosage; Kaplan-Meier Estimate; Middle Aged; Pyrroles/administration & dosage; Sunitinib; Taxoids/administration & dosage; Time Factors; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Receptor, ErbB-2 Type of study: Clinical_trials / Guideline Limits: Adult / Aged / Female / Humans / Middle aged Country/Region as subject: Europa Language: En Year: 2010 Type: Article

Fulltext

XML

PubMed Links

Search on Google